Dynavax's on-hold hepatitis B vaccine succeeds in Phase III
This article was originally published in Scrip
Dynavax Technologies'/Merck & Co's investigational hepatitis B vaccine Heplisav, which is currently on clinical hold, has met its primary endpoint in a Phase III non-inferiority trial comparing it with GlaxoSmithKline's currently marketed hepatitis B vaccine, Engerix-B.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.